HIV-1 persists despite prolonged periods of maximally suppressive antiretroviral therapy, and rapidly rebounds once treatment is stopped. The development of clinical strategies that reduce HIV-1 persistence and may lead to a long-term drug-free remission of HIV-1 infection represents one of the highest priorities in current HIV-1 research. Such clinical interventions require a detailed knowledge of the cell populations that serve as a long- term reservoir for HIV-1, and can be specifically targeted to reduce viral persistence. Here, we hypothesize that HIV-1 can persist life-long by infecting CD4 T cell populations with stem cell-like properties that can self-renew through homeostatic proliferation and simultaneously repopulate differentiated effector T cell populations. Recent work demonstrates that IL-17-secreting CD4 T cells (Th17) are guided by stem-cell like transcriptional signatures, have extremely long in vivo half-lives and can serve as precursor cell populations for differentiated effector CD4 T cells. In this way, Th17 cells are remarkably similar to T memory stem cells (Tscm), a recently- discovered cell population with a multipotent developmental program that can repopulate all CD4 memory cell subsets, while being maintained by homeostatic self-renewal. To determine whether Th17 and Tscm can serve as a reservoir for viral long-term persistence, we will quantify the amount of HIV-1 DNA and replication- competent virus in these cells, and longitudinally compare viral sequences from these cells to more differentiated T cell subsets and plasma sequences. As a possible strategy to target stem cell-like T cells, we propose to focus on pharmaceutical agents that manipulate wnt/beta-catenin, a phylogenetically-conserved stem cell-specific signaling pathway that maintains the quiescence and multipotency of stem cell-like T cells, and in this way may contribute to long-term HIV-1 persistence. Pharmaceutical targeting of the beta-catenin pathway is currently explored in clinical studies to eliminate cancer stem cells, a small group of long-lived, self- renewing cells with strong oncogenic potential that persist despite classical antineoplastic therapy and in that sense may resemble latently HIV-1 infected stem cell-like T cells that persist despite HAART. Using an existing small molecule inhibitor of the wnt/beta-catenin signaling pathway with an excellent safety/tolerability profile that is currently in phase I clinical trials or eradicating cancer stem cells, we will test whether pharmaceutical targeting of wnt/beta-catenin can be used to induce differentiation of HIV-1 infected T cells with stem cell-like properties and to limit HIV-1 persistence. By defining stem cell-like qualities of immune memory that support HIV-1 persistence, and evaluating possible interventional options to target these, the proposed studies may critically advance the quest for inducing long-term drug-free remissions of HIV-1 infection and lead to translational clinical studies evaluating wnt/beta-catenin inhibitors for reducing HIV-1 persistence in vivo.

Public Health Relevance

Replication of HIV-1 can be effectively suppressed with current antiretroviral combination therapy, but HIV-1 persists and rapidly rebounds following treatment cessation. Here, we will investigate how stem cell properties of CD4 T cells, the main target cells for HIV-1, contribute to HIV-1 persistence, and may represent a possible target for interventional strategies to eradicate HIV-1.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21AI106468-02
Application #
8713920
Study Section
AIDS Immunology and Pathogenesis Study Section (AIP)
Program Officer
Stansell, Elizabeth H
Project Start
2013-08-06
Project End
2015-07-31
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
2
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
02199
Martin-Gayo, Enrique; Cole, Michael B; Kolb, Kellie E et al. (2018) A Reproducibility-Based Computational Framework Identifies an Inducible, Enhanced Antiviral State in Dendritic Cells from HIV-1 Elite Controllers. Genome Biol 19:10
Kuo, Hsiao-Hsuan; Ahmad, Rushdy; Lee, Guinevere Q et al. (2018) Anti-apoptotic Protein BIRC5 Maintains Survival of HIV-1-Infected CD4+ T Cells. Immunity 48:1183-1194.e5
Gattinoni, Luca; Speiser, Daniel E; Lichterfeld, Mathias et al. (2017) T memory stem cells in health and disease. Nat Med 23:18-27
Lee, Guinevere Q; Orlova-Fink, Nina; Einkauf, Kevin et al. (2017) Clonal expansion of genome-intact HIV-1 in functionally polarized Th1 CD4+ T cells. J Clin Invest 127:2689-2696
Orlova-Fink, Nina; Chowdhury, Fatema Z; Sun, Xiaoming et al. (2017) Preferential susceptibility of Th9 and Th2 CD4+ T cells to X4-tropic HIV-1 infection. AIDS 31:2211-2215
Lee, Guinevere Q; Lichterfeld, Mathias (2016) Diversity of HIV-1 reservoirs in CD4+ T-cell subpopulations. Curr Opin HIV AIDS 11:383-7
Kiselinova, Maja; De Spiegelaere, Ward; Buzon, Maria Jose et al. (2016) Integrated and Total HIV-1 DNA Predict Ex Vivo Viral Outgrowth. PLoS Pathog 12:e1005472
Paiardini, Mirko; Lichterfeld, Mathias (2016) Follicular T helper cells: hotspots for HIV-1 persistence. Nat Med 22:711-2
Vigano, Selena; Negron, Jordi; Ouyang, Zhengyu et al. (2015) Prolonged Antiretroviral Therapy Preserves HIV-1-Specific CD8 T Cells with Stem Cell-Like Properties. J Virol 89:7829-40
Ouyang, Zhengyu; Buzon, Maria J; Zheng, Lu et al. (2015) Transcriptional Changes in CD8(+) T Cells During Antiretroviral Therapy Intensified With Raltegravir. Open Forum Infect Dis 2:ofv045

Showing the most recent 10 out of 16 publications